Patent cliff fears drive through 2020’s second largest pharma deal

Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe

Get unlimited access to all IAM content